Keymed Biosciences (FRA:64Z) Operating Margin %: -210.65% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:64Z Keymed Biosciences Inc FRA:64Z
44 GF Score
Price €8.45
GF Value €18.50
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Keymed Biosciences Operating Margin %?

Keymed Biosciences FRA:64Z +1.81% 44 Operating Margin % is -210.65% as of Dec. 2025. GuruFocus rates FRA:64Z with a GF Score™ of 44/100 and a GF Value™ of €18.50 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 943 Biotechnology companies, Keymed Biosciences ranks better than 51.75% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Keymed Biosciences's Operating Income for the six months ended in Dec. 2025 was €-55.57 Mil. Keymed Biosciences's Revenue for the six months ended in Dec. 2025 was €26.38 Mil. Therefore, Keymed Biosciences's Operating Margin % for the quarter that ended in Dec. 2025 was -210.65%.

The historical rank and industry rank for Keymed Biosciences's Operating Margin % or its related term are showing as below:

FRA:64Z' s Operating Margin % Range Over the Past 10 Years
Min: -477.96   Med: -136.91   Max: -76.46
Current: -76.89


FRA:64Z's Operating Margin % is ranked better than
51.75% of 943 companies
in the Biotechnology industry
Industry Median: -86.94 vs FRA:64Z: -76.89

Keymed Biosciences's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Keymed Biosciences's Operating Income for the six months ended in Dec. 2025 was €-55.57 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was €-66.36 Mil.

Warning Sign:

Keymed Biosciences Inc has never been profitable in the past 3 years. It lost money every year.


Keymed Biosciences  (FRA:64Z) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Keymed Biosciences Operating Margin % Related Terms


Keymed Biosciences Operating Margin % Historical Data

* Premium members only.

The historical data trend for Keymed Biosciences's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keymed Biosciences Operating Margin % Chart

Keymed Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial -336.73 -477.96 -122.79 -136.92 -76.46

Keymed Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,562.21 -677.06 -57.83 -17.92 -210.65

FRA:64Z vs VRTX, REGN, RVMD: Operating Margin % Comparison

For the Biotechnology subindustry, Keymed Biosciences's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Keymed Biosciences Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keymed Biosciences's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Keymed Biosciences's Operating Margin % falls into.


FRA:64Z
44GF Score
Keymed Biosciences Inc FRA:64Z
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Keymed Biosciences Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Keymed Biosciences's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-66.408 / 86.854
=-76.46 %

Keymed Biosciences's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-55.57 / 26.38
=-210.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -210.65% mean?
Keymed Biosciences (FRA:64Z) has a Operating Margin % of -210.65% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Keymed Biosciences and its competitors. According to the industry distribution chart, Keymed Biosciences ranks #455 out of 943 companies in the Biotechnology industry, placing it in the top 48.3%.
Is Keymed Biosciences' Operating Margin % too high?
Keymed Biosciences' current Operating Margin % is -210.65%. Based on the distribution chart, Keymed Biosciences ranks #455 out of 943 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Keymed Biosciences has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Keymed Biosciences' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Keymed Biosciences ranks #455 out of 943 companies for Operating Margin %. This puts Keymed Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Keymed Biosciences and its competitors. Keymed Biosciences's current Operating Margin % is -210.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keymed Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Keymed Biosciences (FRA:64Z) is currently considered Possible Value Trap. The stock's GF Value™ is €18.50, compared to a current price of €8.45 — trading 54.3% below its estimated fair value. The current Operating Margin % is -210.65%. Keymed Biosciences' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Keymed Biosciences (FRA:64Z), the current Operating Margin % is -210.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Keymed Biosciences (FRA:64Z) Overvalued in 2026?

Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued. The current stock price of €8.45 is trading 54.3% below its estimated GF Value™ of €18.50. GuruFocus considers Keymed Biosciences to be Possible Value Trap.

Key valuation signals for FRA:64Z:

  • Operating Margin %: -210.65%
  • GF Value™: €18.50 vs. price of €8.45 (54.3% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the FRA:64Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Keymed Biosciences Business Description

Other Exchanges 02162:Hong Kong
Address No. 669 Fenghuang Road, Shuangliu District, Chengdu, Sichuan, CHN, 610219
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
44GF Score

Get the complete analysis for FRA:64Z

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.45
Price
€18.50
GF Value